Author details

Full Name

Marie Pancera

Affiliation

ORCID

Career Start Year

2003

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36781872	Cross-protective antibodies against common endemic respiratory viruses.		2023
36971561	Direct Blockade of the Norovirus Histo-Blood Group Antigen Binding Pocket by Nanobodies.		2023
36513069	Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding.		2023
37198165	Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9.	Nat Commun	2023
36931276	Cryo-EM structures of anti-malarial antibody L9 with circumsporozoite protein reveal trimeric L9 association and complete 27-residue epitope.		2023
35411021	Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.	Communications Biology	2022
35705092	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.	Cell Reports Medicine	2022
35507661	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.	Science advances	2022
35736810	Highly protective antimalarial antibodies via precision library generation and yeast display screening.	Journal of Experimental Medicine	2022
34559844	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization.	PLoS Pathog	2021
34237283	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.	Cell Rep	2021
33803622	Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.	Vaccines	2021
34289363	Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.	Cell Reports	2021
33791692	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.	bioRxiv	2021
33951425	Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.	Cell Reports	2021
33876699	Protective antibodies against human parainfluenza virus type 3 infection.	mAbs	2021
33661302	Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites.	J Exp Med	2021
34788599	Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.	Immunity	2021
33110068	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.	Nature Communications	2020
31704807	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses.	J Exp Med	2020
32935094	Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization.		2020
32577631	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.		2020
32561270	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.	Immunity	2020
33114742	Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.	Viruses	2020
32946741	A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.	Immunity	2020
31345930	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.	Journal of Experimental Medicine	2019
31801073	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.	Cell Reports	2019
31732167	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.	Immunity	2019
31345931	Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses.	Journal of Experimental Medicine	2019
29554083	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.	Nat Med	2018
30403372	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.	Elife	2018
29451984	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.	ACS Infect Dis	2018
29311557	Publisher Correction: The Î²20-Î²21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions.	Nature Communications	2018
29669253	An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.	Immunity	2018
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
28275193	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.	Journal of Virology	2017
28825711	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.	Nature Chemical Biology	2017
28422787	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.		2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
29051495	The Î²20-Î²21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions.	Nature Communications	2017
28514685	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.	Immunity	2017
29212041	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains.	Cell Reports	2017
28298421	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.	Science Translational Medicine	2017
28133796	Germline-targeting immunogens.	Immunological Reviews	2017
27806295	Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors.	Cell Rep	2016
27114034	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G.	Cell	2016
27174988	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.	Science	2016
27478931	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.	Nat Struct Mol Biol	2016
26413851	V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.	Journal of acquired immune deficiency syndromes (1999)	2016
26689967	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design.	Nat Struct Mol Biol	2016